A double-blind, controlled, randomized trial to evaluate the efficacy of botulinum toxin for the treatment of lumbar myofascial pain in humans

Regional Anesthesia and Pain Medicine

Volumn 35, Issue 3, 2010, Pages 255-260

  De Andrés, José ^a,b   Adsuara, Vicente Martorell ^c   Palmisani, Stefano ^d   Villanueva, Vicente ^b   López Alarcón, Maria Dolores ^b  

^a Valencia University Medical School   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c Centro de Salud Nazaret   (Spain)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BUPIVACAINE; SODIUM CHLORIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; FLUOROSCOPY; HUMAN; ILIOPSOAS MUSCLE; INJECTION SITE EDEMA; LOW BACK PAIN; MALE; MENTAL HEALTH; MUSCLE WEAKNESS; MYOFASCIAL PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUADRATUS LUMBORUM MUSCLE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ACTIVITIES OF DAILY LIVING; AGED; ANESTHETICS, LOCAL; BOTULINUM TOXINS, TYPE A; BUPIVACAINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LUMBOSACRAL REGION; MALE; MIDDLE AGED; MYOFASCIAL PAIN SYNDROMES; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 77952340610     PISSN: 10987339     EISSN: None     Source Type: Journal    
DOI: 10.1097/AAP.0b013e3181d23241     Document Type: Article

References (47)

1. Airaksinen O, Brox JI, Cedraschi C, et al. Chapter 4. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J. 2006;15(suppl 2): S192-S300.
2. Linton SJ. The socioeconomic impact of chronic back pain: is anyone benefiting? Pain. 1998;75:163-168.
3. Chou R, Atlas SJ, Stanos SP, Rosenquist RW. Nonsurgical interventional therapies for low back pain: a review of the evidence for an American Pain Society Clinical Practice Guideline. Spine. 2009;34:1078-1093.
4. Chou R, Baisden J, Carragee EJ, Resnick DK, Shaffer WO, Loeser JD. Surgery for low back pain: a review of the evidence for an American Pain Society Clinical Practice Guideline. Spine. 2009;34:1094-1109.
5. Chou R, Loeser JD, Owens DK, et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. Spine. 2009;34:1066-1077.
6. Porterfield JA, DeRosa C. Mechanical Low Back Pain: Perspectives in Functional Anatomy. Philadelphia, PA: Saunders; 1998.
7. Gerwin RD. Classification, epidemiology, and natural history of myofascial pain syndrome. Curr Pain Headache Rep. 2001;5:412-420.
8. McGill GM. Low back stability: from formal description to issues for performance and rehabilitation. Exerc Sport Sci Rev. 2001;29:26-31.
9. Njoo KH, Van der Does E. The occurrence and inter-rater reliability of myofascial trigger points in the quadratus lumborum and gluteus medius: a prospective study in non-specific low back pain patients and controls in general practice. Pain. 1994;58:317-323.
10. Raj PP. Treatment algorithm overview: BoNT therapy for pain. Pain Pract. 2004;4(suppl 1): S54-S67.
11. Travell JG, Simons DG. Myofascial Pain and Dysfunction: The Trigger Point Manual. Baltimore, MD: Williams & Wilkins; 1983.
12. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int. 2005;25:604-611.
13. Jeynes LC, Gauci CA. Evidence for the use of botulinum toxin in the chronic pain setting-a review of the literature. Pain Pract. 2008;8:269-276.
14. Scott NA, Guo B, Barton PM, Gerwin RD. Trigger point injections for chronic non-malignant musculoskeletal pain: a systematic review. Pain Med. 2009;10:54-69.
15. De Andres J, Cerda-Olmedo G, Valia JC, Monsalve V, Lopez A, Minguez A. Use of botulinum toxin in the treatment of chronic myofascial pain. Clin J Pain. 2003;19:269-275.
16. Monsalve V, Soriano J, De Andres J. Utilidad del Indice de Lattinen (IL) en la evaluación del dolor crónico: relaciones con afrontamiento y calidad de vida. Rev Soc Esp Dolor. 2006;13:216-229.
17. Gronblad M, Hupli M, Wennerstrand P, et al. Intercorrelation and test-retest reliability of the Pain Disability Index (PDI) and the Oswestry Disability Questionnaire (ODQ) and their correlation with pain intensity in low back pain patients. Clin J Pain. 1993;9:189-195.
18. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression scale. Acta Psychiatr Scand. 1983;67:361-370.
19. Spielberger CD, Gorsuch RL, Lushene RE. STAI Cuestionario de Ansiedad Rasgo y Ansiedad Estado. Madrid, Spain: TEA Ediciones; 1973.
20. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149-158.
21. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11:116-128.
22. Borg-Stein J, Simons DG. Focused review: myofascial pain. Arch Phys Med Rehabil. 2002;83: S40-S47, S48-S49.
23. Hubbard DR, Berkoff GM. Myofascial trigger points show spontaneous needle EMG activity. Spine. 1993;18:1803-1807.
24. Humphrey AR, Nargol AV, Jones AP, Ratcliffe AA, Greenough CG. The value of electromyography of the lumbar paraspinal muscles in discriminating between chronic-low-back-pain sufferers and normal subjects. Eur Spine J. 2005;14:175-184.
25. Kamaz M, Kiresi D, Oguz H, Emlik D, Levendoglu F. CT measurement of trunk muscle areas in patients with chronic low back pain. Diagn Interv Radiol. 2007;13:144-148.
26. Panjabi MM. A hypothesis of chronic back pain: ligament subfailure injuries lead to muscle control dysfunction. Eur Spine J. 2006;15:668-676.
27. Hsieh CY, Hong CZ, Adams AH, et al. Interexaminer reliability of the palpation of trigger points in the trunk and lower limb muscles. Arch Phys Med Rehabil. 2000;81:258-264.
28. de Franca GG, Levine LJ. The quadratus lumborum and low back pain. J Manipulative Physiol Ther. 1991;14:142-149.
29. Fryer G, Morris T, Gibbons P. Paraspinal muscles and intervertebral dysfunction: part two. J Manipulative Physiol Ther. 2004;27:348-357. (Pubitemid 38759590)
30. Hides J, Stanton W, Freke M, Wilson S, McMahon S, Richardson C. MRI study of the size, symmetry and function of the trunk muscles among elite cricketers with and without low back pain. Br J Sports Med. 2008;42:509-513.
31. Hides JA, Belavy DL, Stanton W, et al. Magnetic resonance imaging assessment of trunk muscles during prolonged bed rest. Spine. 2007;32:1687-1692.
32. Kuan TS, Chen JT, Chen SM, Chien CH, Hong CZ. Effect of botulinum toxin on endplate noise in myofascial trigger spots of rabbit skeletal muscle. Am J Phys Med Rehabil. 2002;81:512-520.
33. Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve. 1993;16:964-969.
34. Rogozhin AA, Pang KK, Bukharaeva E, Young C, Slater CR. Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A. J Physiol. 2008;586:3163-3182.
35. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain. 2000;85:101-105.
36. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008;28:3689-3696.
37. Foran PG, Davletov B, Meunier FA. Getting muscles moving again after botulinum toxin: novel therapeutic challenges. Trends Mol Med. 2003;9:291-299.
38. Meunier FA, Lisk G, Sesardic D, Dolly JO. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci. 2003;22:454-466.
39. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125-133.
40. Foster KA, Bigalke H, Aoki KR. Botulinum neurotoxin-from laboratory to bedside. Neurotox Res. 2006;9:133-140.
41. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64:274-283.
42. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain. A randomized double-blind crossover trial. Neurology. 2009;72:1473-1478.
43. Ferrante FM, Bearn L, Rothrock R, King L. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology. 2005;103:377-383.
44. Lew HL, Lee EH, Castaneda A, Klima R, Date E. Therapeutic use of botulinum toxin type A in treating neck and upper-back pain of myofascial origin: a pilot study. Arch Phys Med Rehabil. 2008;89:75-80.
45. Kilkenny M, Deane K, Smith KA, Eyre S. Non-invasive physical treatments of myofascial pain. Cochrane Database Syst Rev. 2006;8: CD006147.
46. Childers MK, Wilson DJ, Gnatz SM, Conway RR, Sherman AK. Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. Am J Phys Med Rehabil. 2002;81:751-759.
47. Zink W, Graf BM. Local anesthetic myotoxicity. Reg Anesth Pain Med. 2004;29:333-340. (Pubitemid 39055660)